CDC warns of new deadly super fungus

The Centers for Disease Control and Prevention (CDC) has issued a warning about a fast-spreading, deadly fungus that has been detected in 28 states. 

The emerging fungus, Candida auris (C. auris), has been spreading across healthcare facilities at an “alarming rate,” the CDC said. Of particular concern is that the fungus is resistant to antifungal drugs, making infections hard to treat. The fungus is also easily spread in healthcare facilities and can lead to high death rates with severe infections. 

Researchers from the CDC penned an article in Annals of Internal Medicine about their findings on the spread of the virus. Since being first reported in 2016, C. auris has continued to spread across the United States, and the number of cases resistant to echinocandins, a class of antifungal drugs, has risen over the past few years.

“The rapid rise and geographic spread of cases is concerning and emphasizes the need for continued surveillance, expanded lab capacity, quicker diagnostic tests, and adherence to proven infection prevention and control,” Meghan Lyman, MD, lead author of the paper and CDC epidemiologist, said in a statement.

In total, 3,270 clinical cases (in which infection is present) and 7,413 screening cases (in which the fungus is detected but not causing infection) have been reported through December 31, 2021. The most rapid rise in clinical cases has occurred from 2020 to 2021, and the CDC has seen increased cases for 2022. Between 2019 and 2021, 17 states reported their first-ever cases of C. auris

Some of the reasons for the increase in cases is due to poor general infection prevention and control (IPC) practices in healthcare facilities. Thought cases may also be up “because of enhanced efforts to detect cases, including increased colonization screening, a test to see if someone has the fungus somewhere on their body but does not have an infection or symptoms of infection,” the CDC said.

In addition, the impact and strain of the COVID-19 pandemic on the nation’s healthcare resources may also play a contributing role in the rapid spread of the fungus, the agency acknowledged.

The CDC will continue to track C. auris and has urged healthcare providers to be on the lookout for new introductions of C. auris from patients who received healthcare elsewhere in the United States and abroad where the fungus has been present. 

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.